Reduced Antibody Responses to the Pandemic (H1N1) 2009 Vaccine after Recent Seasonal Influenza Vaccination

Choi, Yoon Seok; Baek, Yun Hee; Kang, Wonseok; Nam, Seung‐Joo; Lee, Jino; You, Sooseong; Chang, Dongwoo; Youn, Jong-Chan; Choi, Young Ki; Shin, Eui‐Cheol

doi:10.1128/cvi.05053-11

Cited by 38 publications

(34 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The low levels of binding to DENV2 detected validated our hypothesis that these plasmablasts resulted from the reactivation of MBCs from a past DENV1 exposure, rather than as part of a naive response to the current DENV2 infection. OAS has been well described for antibody responses to repeated influenza virus exposures (47)(48)(49)(50), and a few reports have demonstrated this phenomenon in the secondary dengue virus B cell response, as well (29,51,52). Our data strongly suggest that OAS may play a role in the secondary dengue virus immune response and result in decreased binding affinity and neutralization potency against the infecting serotype.…”

Section: Discussionmentioning

confidence: 50%

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts

Priyamvada

Cho

Onlamoon

et al. 2016

J Virol

106

123

View full text Add to dashboard Cite

Dengue virus (DENV) infection results in the production of both type-specific and cross-neutralizing antibodies. While immunity to the infecting serotype is long-lived, heterotypic immunity wanes a few months after infection. Epidemiological studies link secondary heterotypic infections with more severe symptoms, and cross-reactive, poorly neutralizing antibodies have been implicated in this increased disease severity. To understand the cellular and functional properties of the acute dengue virus B cell response and its role in protection and immunopathology, we characterized the plasmablast response in four secondary DENV type 2 (DENV2) patients. Dengue plasmablasts had high degrees of somatic hypermutation, with a clear preference for replacement mutations. Clonal expansions were also present in each donor, strongly supporting a memory origin for these acutely induced cells. We generated 53 monoclonal antibodies (MAbs) from sorted patient plasmablasts and found that DENV-reactive MAbs were largely envelope specific and cross neutralizing. Many more MAbs neutralized DENV than reacted to envelope protein, emphasizing the significance of virion-dependent B cell epitopes and the limitations of envelope protein-based antibody screening. A majority of DENV-reactive MAbs, irrespective of neutralization potency, enhanced infection by antibody-dependent enhancement (ADE). Interestingly, even though DENV2 was the infecting serotype in all four patients, several MAbs from two patients neutralized DENV1 more potently than DENV2. Further, half of all type-specific neutralizing MAbs were also DENV1 biased in binding. Taken together, these findings are reminiscent of original antigenic sin (OAS), given that the patients had prior dengue virus exposures. These data describe the ongoing B cell response in secondary patients and may further our understanding of the impact of antibodies in dengue virus pathogenesis. Dengue viruses (DENV) cause an estimated 390 million infections worldwide every year (1). With as many as 500,000 cases of severe dengue-related hospitalizations per year, dengue has emerged as one of the most critical arboviral diseases in the world today (2). There are four serotypes of dengue viruses (DENV1 to -4), and each can cause acute infection with a wide spectrum of symptoms (3). Clinical disease can range from self-limiting, mild febrile illness to dengue hemorrhagic fever (DHF) and the fatal dengue shock syndrome (DSS) (3-5). Individuals infected with dengue virus generate serum antibody titers that provide longterm protection against future homotypic infections (6). However, in cases of heterotypic infection, several seroepidemiological studies suggest that prior DENV exposure and preexisting antibody may be risk factors for severe disease (7-11). Furthermore, severe DENV infections typically evolve into DHF/DSS 3 to 7 days after fever onset (3), a time associated with a decline in viremia but a rise in serum antibody levels (12, 13). Consequently, in addition to its role in viral clearance, the...

show abstract

Section: Discussionmentioning

confidence: 50%

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts

Priyamvada

Cho

Onlamoon

et al. 2016

J Virol

106

123

View full text Add to dashboard Cite

show abstract

“…Так, статистический анализ полученных результатов показал высокие значе-ния коэффициента Спирмена (от -0,71 до -0,84), отражающие существование четко выраженной обратной зависимости между уровнями CD8 В работе американских авторов [15] совер-шенно справедливо поставлен вопрос о выборе оптимальных сроков между введением прай-мирующих и бустирующих вакцин против по-тенциально пандемических вирусов гриппа А. Это важно с точки зрения развития полноцен-ной поствакцинальной иммунологической па-мяти на праймирование. Показано, что корот-кий период (1-3 месяца) между праймирующей и бустирующей прививками ИГВ не вызывал усиление гуморального иммунного ответа на по- [9]. В исследовании по праймированию людей ЖГВ H5N1 с последующим через 5 лет бустированием ИГВ H5N1 приведены убеди-тельные доказательства сохранения поствакци-нальной В-клеточной иммунологической памяти к праймирующему вирусу не менее этого срока [18].…”

Section: индукция иммунологической памяти живой гриппозной вакциной Aunclassified

Induction of Long-Term T and B Cell Memory Immunity to Influenza a Virus (H5n1) in Persons Vaccinated With Live Influenza a Vaccine (H5n2)

Losev¹,

Donina²,

Petukhova³

et al. 2017

Med. immunol.

View full text Add to dashboard Cite

“…Y.A. Сhoi et al [27] обнаружили, что 18-20-летние студенты, ранее многократно вакцинированные вак-цинами, предназначенными для сезонной вакцинации по гриппу, реагировали на гриппозную вакцину, раз-работанную для противодействия распространению пандемического вируса сероподтипа рH1N1 (pandemic H1N1 2009; pH1N1), значительно слабее, чем ранее не вакцинированные. Однако выяснить, какая вакци-нация стала причиной антигенного импринтинга, ис-следователям не удалось, так как за последние 15 лет в состав вакцин для сезонной вакцинации включа-лось шесть различных штаммов (!)…”

unclassified

Неугодная Иммунология

Supotnytskyi

2022

View full text Add to dashboard Cite

На допомогу практикуючому лікарю To Help PractitionerДекларируемые для врачей представления об им-мунологии находятся в очевидном противоречии с ту-пиковыми результатами экспериментов по созданию эффективных вакцин против ВИЧ, вирусов, возбудите-лей гриппа, энцефалитов, гепатита С, геморрагических лихорадок и ряда других опасных вирусных, бактери-альных и паразитарных инфекций. Однако в отечест-венной учебной литературе врачам предлагается упро-щенное объяснение механизмов работы иммунной системы, основанное на описании взаимодействия не-коего «идеального антигена» с идеальной иммунной си-стемой [2-5], что никогда не встречается при инфекци-онных, эпидемических и поствакцинальных процессах, но позволяет лоббистам фармкомпаний обосновывать любые массовые вакцинации населения. Такая филь-трация знаний на «угодные» и «неугодные», по мнению профессора И.В.

show abstract

Reduced Antibody Responses to the Pandemic (H1N1) 2009 Vaccine after Recent Seasonal Influenza Vaccination

Cited by 38 publications

References 16 publications

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts

Induction of Long-Term T and B Cell Memory Immunity to Influenza a Virus (H5n1) in Persons Vaccinated With Live Influenza a Vaccine (H5n2)

Неугодная Иммунология

Contact Info

Product

Resources

About